Table. 1.

Table 1

Patient and sample characteristics

Characteristic	N (%)
Patients	54
Age, yr, median (range)	9 (1–18)
Sex, Male:Female	1:1.1
Genetic abnormalities
BCR::ABL1	8 (14.8)
TCF3::PBX1	7 (13.0)
ETV6::RUNX1	6 (11.1)
KMT2A rearrangement	1 (1.9)
Other karyotypic abnormalities	25 (46.3)
Normal karyotype	7 (13.0)
Samples	139
Post-induction	35 (25.2)
Post-consolidation	34 (24.5)
Post-maintenance	14 (10.1)
Post-chimeric antigen receptor T cell therapy	16 (11.6)
Post-immunotherapy (blinatumomab or inotuzumab)	6 (4.3)
Post-hematopoietic stem cell transplantation	34 (24.5)